This map shows the geographic impact of D. Scevola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Scevola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Scevola more than expected).
This network shows the impact of papers produced by D. Scevola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Scevola. The network helps show where D. Scevola may publish in the future.
Co-authorship network of co-authors of D. Scevola
This figure shows the co-authorship network connecting the top 25 collaborators of D. Scevola.
A scholar is included among the top collaborators of D. Scevola based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with D. Scevola. D. Scevola is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Corbella, Marta, et al.. (2014). Antibacterial activity and cytotoxic effect of SIAB-GV3.. PubMed. 37(4). 535–41.6 indexed citations
Scevola, D., et al.. (2000). Reversal of cachexia in patients treated with potent antiretroviral therapy.. PubMed. 10(6). 365–9, 371.16 indexed citations
5.
Barbarini, Giorgio, Gabriella Bottari, Benvenuto Grisorio, et al.. (1994). Beta-interferon therapy of chronic C hepatitis in 85 patients: Results after one year of treatment. 9(1). 25–28.1 indexed citations
6.
Scevola, D., et al.. (1993). IL RUOLO DEL LATTITOLO NELLA REGOLAZIONE DELLA FLORA BATTERICA INTESTINALE IN CORSO DI EPATITE. 45. 906–918.1 indexed citations
Scevola, D., et al.. (1989). [Lactitol and neomycin: monotherapy or combined therapy in the prevention and treatment of hepatic encephalopathy?].. PubMed. 129(2). 105–11.7 indexed citations
9.
Scevola, D., et al.. (1986). Chemiluminescence, phagocytosis, chemotaxis and killing activity of human leukocytes exposed to Clindamycin.. PubMed. 9(2). 209–14.3 indexed citations
10.
Scevola, D., et al.. (1985). Costs and benefits of diagnostic and therapeutic methods in Salmonella infections.. PubMed. 64(5). 376–80.4 indexed citations
11.
Scevola, D., et al.. (1984). Flavonoids and hepatic cyclic monophosphates in liver injury.. PubMed. 63(1). 77–82.20 indexed citations
12.
Scevola, D., et al.. (1980). Bacterial toxins and glucagon in liver cAMP regulation: a physiopathological role in liver diseases?. PubMed. 59(6). 655–61.1 indexed citations
13.
Baldini, Mario, et al.. (1979). CSF shunt infection management in adult age.. PubMed. 35. 53–7.3 indexed citations
14.
Scevola, D., et al.. (1979). Control of endotoxinemia in liver disease by lactulose and paromomycin.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 58(3). 242–7.8 indexed citations
15.
Scevola, D., et al.. (1979). Investigations on the actions of silybin on regenerating rat liver. Effects on Kupffer's cells.. PubMed. 29(7). 1024–8.1 indexed citations
Scevola, D., et al.. (1975). [Studies of the clinical effectiveness of the mucolytic drug, S-carboxymethylcysteine, in the therapy of acute and chronic bronchitis].. PubMed. 66(25). 1187–97.2 indexed citations
19.
Feo, Vincenzo De, et al.. (1973). Enhanced in vitro phagocytic power of macrophages from PPD-stimulated skin sites in human subjects hypersensitive to PPD.. PubMed. 14(3). 371–6.7 indexed citations
20.
Carosi, Giampiero, et al.. (1971). [Significance of the cellular factors in the antibacterial response].. PubMed. 23(6). 317–43.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.